LGND Stock: Price, Earnings History and SEC Filings
Ligand Pharmaceuticals Incorporated (LGND) last traded at $322.75, up 1.71% on the latest session and up 3.3% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $-1.43 against an analyst estimate of $1.42, a miss of 200.7%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
LGND earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 29, 2026 | $-1.43 | $1.42 | -200.70% |
| Jun 2026 | Aug 6, 2026 | $2.22 | $1.34 | +65.67% |
| Mar 2026 | May 7, 2026 | $-0.67 | $0.98 | -168.37% |
| Dec 2025 | Feb 26, 2026 | $2.12 | $0.63 | +236.51% |
LGND beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How LGND reacts to earnings
Across its last 8 earnings releases, LGND moved 3.6% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-29 | Before open | -0.45% |
| 2026-08-06 | Before open | -0.80% |
| 2026-05-07 | Before open | -9.55% |
| 2026-02-26 | Before open | +2.50% |
| 2025-11-06 | Before open | +9.37% |
| 2025-08-07 | Before open | +2.75% |
| 2025-05-08 | Before open | -2.94% |
| 2025-02-27 | Before open | +0.57% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
LGND financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $268M | $124M | $49M | 46.4% | $6.13 |
| 2024 | $167M | -$4M | $95M | -2.4% | $-0.22 |
| 2023 | $131M | $52M | $46M | 39.7% | $2.94 |
| 2022 | $196M | -$33M | $120M | -17.0% | $-1.98 |
| 2021 | $242M | $57M | $70M | 23.7% | $3.31 |
| 2020 | $164M | -$3M | $50M | -1.8% | $-0.18 |
| 2019 | $120M | $629M | -$32M | 523.2% | $31.85 |
| 2018 | $251M | $143M | $193M | 57.0% | $5.96 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for LGND
- 10-Q · Oct 30, 2026
- 8-K · Oct 29, 2026Results of operations, Financial statements and exhibits
- 8-K · Sep 24, 2026Regulation FD disclosure, Other events
- 8-K · Sep 22, 2026Regulation FD disclosure, Financial statements and exhibits
- 10-Q · Aug 7, 2026
- 8-K · Aug 6, 2026Results of operations, Financial statements and exhibits
- 8-K · Jul 14, 2026Material agreement, Acquisition or disposal completed, New financial obligation
- 8-K · Jun 25, 2026Material agreement, New financial obligation, Unregistered share sale
- 8-K · Jun 22, 2026Material agreement, Other events, Financial statements and exhibits
- 8-K · Jun 9, 2026Officer or director change, Shareholder vote
Insider filing activity
LGND insiders filed 6 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
LGND news
- Ligand Pharmaceuticals Sees Strong Royalty Growth Ahead of Investor Day, Oppenheimer SaysOct 30, 2026 · finance.yahoo.com
- Ligand Pharmaceuticals (LGND) Stock Price Ignores Q3 Earnings Losses And Royalty StrengthOct 30, 2026 · finance.yahoo.com
- Ligand (LGND) Q3 2026 Earnings Call TranscriptOct 30, 2026 · fool.com
- Ligand Pharmaceuticals Incorporated Q3 2026 Earnings Call SummaryOct 30, 2026 · app.moby.co
- What Ligand Pharmaceuticals (LGND) Said on Its Q3 Earnings CallOct 29, 2026 · marketbeat.com
- Ligand: Q3 Earnings SnapshotOct 29, 2026 · finance.yahoo.com
- Ligand Reports Third Quarter 2026 Financial ResultsOct 29, 2026 · finance.yahoo.com
- Ligand to Participate in November Investor ConferencesOct 27, 2026 · finance.yahoo.com
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated (LGND) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.